Tokio Marine Asset Management Co. Ltd. Purchases 748 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Tokio Marine Asset Management Co. Ltd. increased its stake in Thermo Fisher Scientific Inc. by 7.0%, owning 11,464 shares worth approximately $5.7 million as of the end of the last quarter.
• Insider activity included CEO Marc N. Casper selling 10,000 shares for over $4.5 million, reducing his position by 7.99% while maintaining shares valued at about $52 million.
• Equities analysts generally hold a positive outlook on Thermo Fisher, with a consensus rating of "Moderate Buy" and an average target price of $593.00, despite some recent price target adjustments.

Tokio Marine Asset Management Co. Ltd. boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,464 shares of the medical research company's stock after buying an additional 748 shares during the period. Tokio Marine Asset Management Co. Ltd.'s holdings in Thermo Fisher Scientific were worth $5,704,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMO. GAMMA Investing LLC grew its stake in Thermo Fisher Scientific by 60,610.9% in the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock valued at $1,203,859,000 after acquiring an additional 2,415,346 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its stake in Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after purchasing an additional 1,433,444 shares during the last quarter. Nuveen LLC acquired a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at about $532,360,000. Kovitz Investment Group Partners LLC increased its position in Thermo Fisher Scientific by 1,905.4% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after purchasing an additional 858,193 shares in the last quarter. Finally, Farallon Capital Management LLC increased its position in Thermo Fisher Scientific by 73.8% during the 4th quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock worth $641,577,000 after purchasing an additional 523,800 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TMO. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective on the stock in a research note on Friday, July 11th. Robert W. Baird raised their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday, April 23rd. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $52,037,916.68. This represents a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,400 shares of company stock worth $8,345,792. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded up $0.83 during trading hours on Thursday, reaching $485.62. 1,955,228 shares of the company were exchanged, compared to its average volume of 3,096,282. The firm has a market cap of $183.38 billion, a price-to-earnings ratio of 28.09, a PEG ratio of 2.59 and a beta of 0.74. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a 50-day moving average of $433.08 and a 200 day moving average of $461.44. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The company's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company earned $5.37 earnings per share. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.